Adaptive Biotechnologies Quarterly Cash Flow Statement
NASDAQ: ADPTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Adaptive Biotechnologies free cash flow
In the quarter ended Jun 30, 2026, Adaptive Biotechnologies generated -$6.4 million of operating cash flow and spent $1.2 million on capital expenditures. That left free cash flow of -$7.6 million, a free-cash-flow margin of -10.6% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Adaptive Biotechnologies cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -39.94M | -20.02M | -13.58M | 9.54M | -25.59M | -29.83M | -33.72M | -32.10M | -46.25M | -47.53M | -69.47M | -50.33M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 3.27M | 3.39M | 3.65M | 3.97M | 4.07M | 4.29M | 3.93M | 4.16M | 4.57M | 5.21M | 2.76M | 5.76M |
| Stock-Based Compensation | 11.12M | 11.93M | 12.72M | 13.26M | 13.36M | 12.15M | 12.83M | 13.52M | 12.96M | 14.30M | 15.56M | 15.34M |
| Change in Working Capital | 2.33M | -3.60M | 67.00K | -31.30M | -2.12M | -14.10M | 6.01M | -11.40M | 5.04M | -7.75M | -1.53M | -16.36M |
| Operating Cash Flow | -6.40M | -9.54M | 2.06M | -7.13M | -12.43M | -28.48M | -12.49M | -27.07M | -17.30M | -38.35M | -26.93M | -46.68M |
| Capital Expenditures | -1.18M | -796.00K | -636.00K | -409.00K | -655.00K | -1.26M | -80.00K | -344.00K | -1.73M | -1.51M | -1.30M | -2.78M |
| Investing Cash Flow | -43.48M | 9.14M | -8.25M | 17.28M | 3.35M | 25.57M | 22.12M | 5.29M | 5.88M | 44.51M | 3.21M | 26.14M |
| Financing Cash Flow | 142.19M | 7.50M | 21.66M | 1.68M | 1.61M | 5.45M | 127.00K | 40.00K | 30.00K | 44.00K | 87.00K | 17.00K |
| Net Change in Cash | 92.31M | 7.11M | 15.46M | 11.84M | -7.47M | 2.54M | 9.76M | -21.74M | -11.40M | 6.20M | -23.64M | -20.53M |
| Free Cash Flow | -7.58M | -10.33M | 1.42M | -7.54M | -13.09M | -29.74M | -12.57M | -27.41M | -19.03M | -39.86M | -28.23M | -49.46M |
This table shows 12 quarterly periods of Adaptive Biotechnologies's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ADPT's reporting calendar. What is a cash flow statement?